GLP-1 drugs and energy claims: What the studies actually show

What's this video probably claiming?

Based on the caption and hashtag cluster, @wellnessbyhaleigh is almost certainly describing her experience on a GLP-1 receptor agonist, likely semaglutide or tirzepatide, framed around reduced inflammation, dramatically improved energy levels, and broader life transformation. The hashtags #insulinresistance and #pcos suggest she may be positioning GLP-1 therapy as a solution for those specific conditions, not just weight loss. The "message me" call to action is a classic soft referral pattern, common among creators who direct followers toward a telehealth affiliate or personal program. Whether or not money changes hands, this structure functions as a testimonial-first, evidence-later pitch. That's worth scrutinizing carefully, because personal transformation narratives are compelling and often genuinely true for the individual while simultaneously leaving out the clinical fine print that would matter to someone else considering the same path.

What does the science actually show?

The energy and fatigue picture with GLP-1 drugs is more complicated than most TikTok content admits. Wilding et al. (2021, NEJM) showed semaglutide 2.4mg produced roughly 14.9% mean body weight loss over 68 weeks, and participants reported improvements in physical functioning. Jastreboff et al. (2022, NEJM) found tirzepatide at 15mg achieved up to 22.5% weight loss at 72 weeks. Weight loss at that scale does tend to reduce fatigue associated with obesity and insulin resistance. On the PCOS side, a 2023 trial published in Fertility and Sterility by Xiao et al. found semaglutide improved hormonal markers and self-reported energy in women with PCOS and obesity. However, the early weeks of GLP-1 therapy frequently cause nausea, fatigue, and GI distress, which creators rarely mention. Saying you have "more energy than ever" likely reflects a later-stage experience, not the full arc.

Where does the social media noise diverge from clinical reality?

The inflammation angle is where things get slippery. GLP-1 receptors are present in immune cells, and there is preliminary research suggesting anti-inflammatory effects. Drucker (2022, Cell Metabolism) reviewed GLP-1 receptor signaling beyond glucose regulation and noted plausible anti-inflammatory pathways. But that research is largely mechanistic and animal-based. Saying you feel "less inflamed" is subjective. It could reflect weight loss, dietary changes, reduced insulin resistance, better sleep, or placebo effect. The PCOS community in particular latches onto inflammation as a unifying explanation for their symptoms, which is understandable but scientifically premature when applied to personal testimonials. There is also no standardized way for someone at home to measure inflammation, so the claim is not falsifiable. That does not make it wrong, but it does make it unverifiable, and unverifiable claims dressed as personal proof are how people make medical decisions they should be making with a clinician.

What should you actually know?

GLP-1 receptor agonists are legitimate, FDA-approved medications with strong clinical trial data behind specific indications: type 2 diabetes, chronic weight management in adults with obesity or overweight plus a weight-related condition, and cardiovascular risk reduction in certain populations. The SELECT trial (Lincoff et al., 2023, NEJM) showed semaglutide 2.4mg reduced major cardiovascular events by 20% in non-diabetic adults with obesity, which is genuinely significant. For women with PCOS and insulin resistance, there is growing but not yet definitive evidence supporting GLP-1 use. What the science does not support is treating a creator's post-transformation testimonial as a treatment guide. Side effects, contraindications, thyroid C-cell tumor risk (noted in FDA labeling for the semaglutide class), pancreatitis risk, and medication interactions are all real considerations. This class of drugs can be appropriate and effective. It deserves more than a before-and-after caption.